GPX4 and hepatocellular carcinoma: We validated the sensitivity of HCC cells to GPX4 loss using drugs that impair glutathione biosynthesis in vivo (sulfasalazine) or directly inhibit GPX4 in vitro (1S,3R-RSL 3, hereafter referred to as RSL3; Fig. 6A).